These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 2555448

  • 1. Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.
    Morgan AJ, Allison AC, Finerty S, Scullion FT, Byars NE, Epstein MA.
    J Med Virol; 1989 Sep; 29(1):74-8. PubMed ID: 2555448
    [Abstract] [Full Text] [Related]

  • 2. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S, Tarlton J, Mackett M, Conway M, Arrand JR, Watkins PE, Morgan AJ.
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [Abstract] [Full Text] [Related]

  • 3. Not all potently neutralizing, vaccine-induced antibodies to Epstein-Barr virus ensure protection of susceptible experimental animals.
    Epstein MA, Randle BJ, Finerty S, Kirkwood JK.
    Clin Exp Immunol; 1986 Mar; 63(3):485-90. PubMed ID: 3011324
    [Abstract] [Full Text] [Related]

  • 4. Comparative immunogenicity studies on Epstein-Barr virus membrane antigen (MA) gp340 with novel adjuvants in mice, rabbits, and cotton-top tamarins.
    Morgan AJ, Epstein MA, North JR.
    J Med Virol; 1984 Mar; 13(3):281-92. PubMed ID: 6327902
    [Abstract] [Full Text] [Related]

  • 5. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
    Morgan AJ, Finerty S, Lovgren K, Scullion FT, Morein B.
    J Gen Virol; 1988 Aug; 69 ( Pt 8)():2093-6. PubMed ID: 2841417
    [Abstract] [Full Text] [Related]

  • 6. The Leeuwenhoek lecture, 1983. A prototype vaccine to prevent Epstein-Barr virus-associated tumours.
    Epstein MA.
    Proc R Soc Lond B Biol Sci; 1984 Mar 22; 221(1222):1-20. PubMed ID: 6144103
    [Abstract] [Full Text] [Related]

  • 7. Demonstration in vitro of cell mediated immunity to Epstein-Barr virus in cotton-top tamarins.
    Finerty S, Scullion FT, Morgan AJ.
    Clin Exp Immunol; 1988 Aug 22; 73(2):181-5. PubMed ID: 2846217
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant formulations and their mode of action.
    Allison AC, Byars NE.
    Semin Immunol; 1990 Sep 22; 2(5):369-74. PubMed ID: 1966859
    [Abstract] [Full Text] [Related]

  • 9. Immunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.
    Finerty S, Mackett M, Arrand JR, Watkins PE, Tarlton J, Morgan AJ.
    Vaccine; 1994 Oct 22; 12(13):1180-4. PubMed ID: 7839721
    [Abstract] [Full Text] [Related]

  • 10. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine.
    Epstein MA, Morgan AJ, Finerty S, Randle BJ, Kirkwood JK.
    Nature; 1994 Oct 22; 318(6043):287-9. PubMed ID: 2999604
    [Abstract] [Full Text] [Related]

  • 11. Purification and properties of the gp340 component of Epstein-Barr virus membrane antigen in an immunogenic form.
    Morgan AJ, North JR, Epstein MA.
    J Gen Virol; 1983 Feb 22; 64 (Pt 2)():455-60. PubMed ID: 6300296
    [Abstract] [Full Text] [Related]

  • 12. Efficient purification of Epstein-Barr virus membrane antigen gp340 by fast protein liquid chromatography.
    David EM, Morgan AJ.
    J Immunol Methods; 1988 Apr 06; 108(1-2):231-6. PubMed ID: 2832478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The Florey lecture, 1986. Vaccine prevention of virus-induced human cancers.
    Epstein MA.
    Proc R Soc Lond B Biol Sci; 1987 Mar 23; 230(1259):147-61. PubMed ID: 2884667
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Ulaeto D, Wallace L, Morgan A, Morein B, Rickinson AB.
    Eur J Immunol; 1988 Nov 23; 18(11):1689-97. PubMed ID: 2904885
    [Abstract] [Full Text] [Related]

  • 17. A highly sensitive enzyme-linked immunosorbent assay to quantitate antibodies to Epstein-Barr virus membrane antigen gp340.
    Randle BJ, Epstein MA.
    J Virol Methods; 1984 Nov 23; 9(3):201-8. PubMed ID: 6440902
    [Abstract] [Full Text] [Related]

  • 18. Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.
    Epstein MA, Morgan AJ.
    Clin Exp Immunol; 1983 Aug 23; 53(2):257-71. PubMed ID: 6309441
    [No Abstract] [Full Text] [Related]

  • 19. Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses.
    Miller G, Shope T, Coope D, Waters L, Pagano J, Bornkamn G, Henle W.
    J Exp Med; 1977 Apr 01; 145(4):948-67. PubMed ID: 192829
    [Abstract] [Full Text] [Related]

  • 20. Vaccination against Epstein-Barr virus: current progress and future strategies.
    Epstein MA.
    Lancet; 1986 Jun 21; 1(8495):1425-7. PubMed ID: 2872525
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.